27.02.2013 - Xellia Pharmaceuticals and the Statens Serum Institute have kicked-off a collaboration to find new medicines against antibiotic-resistant bacteria.
The 4 -year collaboration of the Norwegian firm with Trondheim-based SINTEF Materials and Chemistry and the Danish Institute (Copenhagen) focusses on developing novel antibiotics to combat multi-drug resistant (MDR), Gram-negative bacteria. Supported with US$3m from the Research Council of Norway, it will target Pseudomonas, Klebsiella, Acinetobacter and Enterobacter species.
Severe sepsis and septic shock due to such infections claim up to 135,000 lives each year in Europe and 215,000 in the US. Resistance to existing antibiotics has become a major healthcare issue worldwide. In the EU alone, infections due to serious hospital-based MDR infections have been reported to cost between €28,500 and €70,100 per surviving patient.
Recently, pan-drug resistant (PDR) and even so-called extensively drug resistant (XDR) Gram-negative bacteria have started to appear, taking the treatment situation to a critical point. The lack of novel antibiotics is significantly compromising the survival and recovery of patients suffering from these infections. At present, only two antibiotic subclasses are still available to treat XDR infections, polymyxins and tigecycline. They have been used for 60-70 years without developing a significant resistance. However, these antibiotics are known to exhibit elevated nephrotoxicity (affecting kidney function) and are, therefore, not ideal for systemic treatment of XDR-infections.
Xellia aims at developing new, polymyxin-like drugs with fewer side-effects. The SINTEF and Statens Serum Institut research groups are specialists in fermentation development and drug testing. Xellia already markets four antibiotics targeting Gram-negative bacteria.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.